Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium chloride 0.9% (University of Zurich)
- Development stage
- Unknown
- Lead developer
- University of Zurich
- Modality
- Small Molecules
- Administration
- Intradermal, Subcutaneous
01
Overview
Sodium chloride 0.9% (normal saline) is an isotonic inorganic salt solution. In the Phase 2 clinical trial NCT03238625 conducted by the University of Zurich, it was utilized as a placebo comparator (IMP4) to evaluate pain during local anesthetic infiltration of lidocaine/epinephrine buffered with sodium bicarbonate. As a placebo, it contains no active anesthetic ingredients, has no specific biological targets, and possesses no therapeutic indication in this context.
- Other names
- 0.9% NaCl0.9% sodium chloridenormal salinephysiological salinesaline solutionSodium cloride 0.9%sterile saline
Beyond the preview
Go deeper on sodium chloride 0.9% (University of Zurich).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium chloride 0.9% (University of Zurich).